Profusa Expands Clinical Applications with Graz Collaboration
Profusa Collaborates with Graz University for Enhanced Patient Monitoring
Profusa, Inc. (NASDAQ: PFSA), a pioneering digital health company based in Berkeley, California, has recently announced an exciting partnership with the Medical University of Graz, Austria. This collaboration, spearheaded by the esteemed Prof. Dr. Marianne Brodmann, focuses on adopting the innovative Lumee oxygen platform in various clinical settings to improve patient monitoring during vascular procedures.
Transforming Clinical Practices with the Lumee Technology
At the heart of this collaboration is the integration of advanced real-time oxygen perfusion data into the clinical routine. Prof. Brodmann, who conducts around 1,500 vascular procedures each year, will implement the Lumee system to enhance patient care. "Real-time data is essential for monitoring patients suffering from critical limb ischemia throughout surgery and recovery,” she shared. Her hands-on experience with Profusa's technology has convinced her of its potential to fulfill pressing clinical needs. Excitingly, this partnership allows for ongoing exploration of how the Lumee system can further benefit clinical communities.
Expertise and Commitment to Innovation
Prof. Dr. Marianne Brodmann brings extensive expertise to this collaboration, holding significant roles in various medical organizations, including her positions in the European Society of Cardiology. Her experience encompasses involvement in over 50 international trials covering crucial topics such as anticoagulation and advanced technologies in endovascular care. With over 100 publications to her credit, Prof. Brodmann stands as a beacon of knowledge in her field.
Ben Hwang, Ph.D., CEO and Chairman of Profusa, expressed enthusiasm about this collaboration, stating, “Our ongoing relationship with Prof. Brodmann validates our Lumee platform’s capabilities. Integrating this technology within her clinical studies not only reinforces our market presence but also drives innovation towards broader applications of our technology.”
About Profusa and Its Vision for the Future
Profusa is dedicated to pioneering a new generation of tissue-integrated sensors capable of delivering continuous, actionable medical data for both personal and professional medical applications. Their innovative approach focuses on developing long-lasting and affordable biosensors that provide reliable biochemical data to clinicians, enhancing their decision-making and patient care processes.
With a commitment to advancing health technologies, Profusa aims to establish a new standard of care through its intelligent data platform, ensuring that healthcare providers have access to the precise information they need to improve patient outcomes.
Frequently Asked Questions
What does the collaboration between Profusa and Graz University entail?
The collaboration focuses on integrating Profusa's Lumee oxygen platform into vascular procedures conducted by Prof. Dr. Brodmann, enhancing patient monitoring and care.
How will the Lumee technology improve patient care?
By providing real-time oxygen perfusion data, the Lumee system enables better monitoring and management of patients, particularly those with critical limb ischemia.
Who is Prof. Dr. Marianne Brodmann?
Prof. Brodmann is a renowned expert in angiology, associated with numerous prestigious medical organizations and publications, furthering research and clinical practices in her field.
What is the significance of the Lumee platform?
The Lumee platform represents a breakthrough in continuous monitoring technology, providing clinicians with vital data to enhance patient care and outcomes during and after procedures.
How does Profusa position itself in the digital health space?
Profusa aims to lead in developing innovative health technologies that offer continuous, reliable data, helping healthcare providers make informed decisions for improved patient care.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
